Innate Pharma's Sezary Syndrome treatment shows strong results. Learn why IPHA stock offers potential with phase 2 data and ...

Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with ...

BOSTON, MA, USA I February 19, 2025 I Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered ...

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.

Utrecht, The Netherlands Thursday, February 20, 2025, 15:00 Hrs [IST] ...

CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

SAN DIEGO, CA, USA I February 19, 2025 I Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and ...

Effects of PF-04236921, an anti-IL-6 antibody, in adults with CD are reported ... For patients who entered the OLE trial as responders and who had been on active drug in the induction period (n=65), ...

Understanding biosimilars, biologics, and the challenges surrounding their regulation and pricing in the pharmaceutical ...

Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...

With the Trump administration announcing plans to impose 25% tariffs on pharmaceuticals, it reignites a critical discussion ...